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Background: Prior studies have suggested that HAART initiation may vary by race/ethnicity. Utilizing the U.S.
military healthcare system, which minimizes confounding from healthcare access, we analyzed whether timing of
HAART initiation and the appropriate initiation of primary prophylaxis among those at high risk for pneumocystis
pneumonia (PCP) varies by race/ethnicity.
Methods: Participants in the U.S. Military HIV Natural History Study from 1998-2009 who had not initiated HAART
before 1998 and who, based on DHHS guidelines, had a definite indication for HAART (CD4 <200, AIDS event or
severe symptoms; Group A), an indication to consider HAART (including CD4 <350; Group B) or electively started
HAART (CD4 >350; Group C) were analyzed for factors associated with HAART initiation. In a secondary analysis,
participants were also evaluated for factors associated with starting primary PCP prophylaxis within four months of
a CD4 count <200 cells/mm3. Multiple logistic regression was used to compare those who started vs. delayed
therapy; comparisons were expressed as odds ratios (OR).
Results: 1262 participants were evaluated in the analysis of HAART initiation (A = 208, B = 637, C = 479 [62
participants were evaluated in both Groups A and B]; 94% male, 46% African American, 40% Caucasian). Race/
ethnicity was not associated with HAART initiation in Groups A or B. In Group C, African American race/ethnicity
was associated with lower odds of initiating HAART (OR 0.49, p = 0.04). Race and ethnicity were also not associated
with the initiation of primary PCP prophylaxis among the 408 participants who were at risk.
Conclusions: No disparities in the initiation of HAART or primary PCP prophylaxis according to race/ethnicity were
seen among those with an indication for therapy. Among those electively initiating HAART at the highest CD4 cell
counts, African American race/ethnicity was associated with decreased odds of starting. This suggests that free
healthcare can potentially overcome some of the observed disparities in HIV care, but that unmeasured factors may
contribute to differences in elective care decisions.
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HIV has become a treatable illness in the era of highly ac-
tive antiretroviral therapy (HAART), and HAART is asso-
ciated with a reduction in morbidity and mortality among
those with severe immunosuppression [1]. There is in-
creasing evidence that HAART is associated with reduced* Correspondence: bagan@idcrp.org
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reproduction in any medium, provided the ormortality among those initiating HAART at higher CD4
cell counts as well [2-7]. Thus the optimal timing of
HAART initiation may result in a more robust immuno-
logic and virologic response, which may improve out-
comes. However there are factors other than the degree of
immune suppression involved in the decision to start
HAART.
Despite the known benefits of HAART, certain groups
appear to be more vulnerable to treatment disparities, and
these disparities have persisted over time. In a U.S. study
of HIV-infected persons, delays of three or more monthsl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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curred more frequently among patients who lacked ac-
cess to care at diagnosis and among those of African
American or Latino race/ethnicity [8]. Delays in the
initiation of HAART and failure to receive PCP pro-
phylaxis occurred more frequently among blacks or
Latinos, women, and the underinsured compared with
other HIV patients [9]. Among a national sample of pa-
tients eligible to receive HAART by published guide-
lines, African American race/ethnicity, female gender
and injection drug use were all associated with de-
creased likelihood of receipt of HAART [10]. Finally, in
patients with HIV treated at multiple clinical sites in the
United Kingdom, black race was associated with start-
ing antiretroviral therapy at a lower CD4 count [11].
The etiology of these disparities is complex and likely
multifactorial. Factors that have been hypothesized from
previous studies include lack of health insurance or other
barriers impeding healthcare access, variations in patient
education or health literacy, and aspects of the physician-
provider relationship [12,13]. Understanding the role these
factors play in creating barriers to optimal care is needed
and may offer an explanation for some of these observed
differences in HIV care and outcomes [14-17].
In this study, we evaluated factors associated with
HAART initiation within a defined time window in a
United States military cohort of persons with HIV. As a
secondary analysis, we also analyzed factors associated
with the initiation of primary pneumocystis pneumonia
(PCP) prophylaxis among persons at highest risk for PCP.
Our population consists of an ethnically diverse group of
early-diagnosed HIV patients with free healthcare and
medications [18]. Furthermore, since military service for
those on active duty provides a stable source of income
and members have a minimum high school education, this
cohort may offer somewhat less confounding due to socio-
economic status. Time windows to evaluate HAART initi-
ation were established based on military policy requiring
that HIV infected active duty members with stable disease
undergo medical evaluation every six months and stand-
ard practice to evaluate those with advanced HIV disease
more frequently, at least every three to four months.
HAART initiation was assessed in accordance with the
U.S. Department of Health and Human Services (DHHS)
guidelines for the use of antiretroviral agents [19], which,
since 1998, have been adopted into the practice of many
U.S. physicians who specialize in HIV care, including those
practicing within the U.S. military system.
Methods
Study population
The U.S. Military HIV Natural History Study (NHS), a
cohort study of military beneficiaries with HIV infection
including active duty personnel, retirees and dependents,enrolled 5261 participants from 1986 to 2009. Active duty
personnel must be HIV negative prior to entry into U.S.
military service, and subsequently undergo HIV screening
every one to five years. Service members and beneficiaries
identified with HIV are referred to military treatment facil-
ities (MTFs) across the U.S. for evaluation and treatment.
Those participating in the study provide written informed
consent prior to assuming a schedule of evaluations by an
HIV specialist at least every six months at one of five par-
ticipating MTFs. Data including demographic characteris-
tics, medical history, and laboratory measurements are
collected at each study visit as previously described [18].
In compliance with the Helsinki Declaration, the NHS
protocol has been reviewed and approved by the institu-
tional review boards (IRBs) centrally and at the study
sites. All subjects provided informed consent for partici-
pation. This analysis was reviewed and approved by the
central IRB.
Participants who were enrolled in the NHS from 1998-
2009 and who had not initiated HAART before 1998 were
included in this substudy. Participants were excluded from
these analyses if they had died (N = 1195), were lost-to-
follow-up (N = 969), or had initiated HAART prior to
January 1, 1998 (N = 1514). The analysis also excluded
those participants who, prior to the three-month window
preceding the first study date, i.e. September 1, 1997, had
a CD4 cell count below 200 cells/mm3, an AIDS-defining
condition, or any severe symptoms (category B symptoms
according to the 1993 Revised Classification System for
HIV Infection, including refractory mucosal candidiasis,
wasting syndrome, pre-invasive cervical cancer, bacillary
angiomatosis, oral hairy leukoplakia, and chronic diarrhea)
[20] (N = 233).
Study design
Participants were followed from the later of January 1,
1998 or their date of initial diagnosis with HIV until meet-
ing criteria for assignment in one of three groups based
on concurrent DHHS criteria. The details of this classifica-
tion as well as changes in DHHS criteria during the study
period of 1998-2009 are summarized in Table 1. The three
groups included:
 Group A – those participants with a definite
indication for HAART. Participants were classified
as “initiators” if they started HAART within four
months of classification or “delayers” if they did not.
Those with less than four months of follow-up be-
tween the date of classification and last study visit
were excluded from analysis (N = 18).
 Group B – those participants with an indication to
consider HAART. Initiators started HAART within
six months of classification and delayers did not
start HAART within this timeframe. Those with less
Table 1 Study group classifications according to changes in the DHHS guidelines for initiation of antiretroviral therapy
in chronically-infected HIV patients1
Group 1998-2000 2001 2002-2004 2005-2007 2008-2009
A • AIDS-defining condition • AIDS-defining condition • AIDS-defining condition • AIDS-defining condition • AIDS-defining condition
• Severe symptoms • Severe symptoms • Severe symptoms • Severe symptoms • Severe symptoms
• CD4+ <200 • CD4+ <200 • CD4+ <200 • CD4+ <200
B • CD4+ <500 • CD4+ >200 but ≤350 • CD4+ >200 but ≤350 • CD4+ >200 but ≤350 • CD4+ >200 but ≤350
• VL >10,000 (bDNA)
or >20,000 (RT-PCR)
C • Elective decision • VL >30,000 (bDNA)
or >55,000 (RT-PCR)
• VL >55,000 (bDNA or RT-PCR) • VL >100,000 (RT-PCR) • CD4+ >350
• CD4+ >350 • CD4+ >350 • CD4+ >350 • Other elective decision
• Other elective decision • Other elective decision • Other elective decision
1Guideline statements of “some would treat” were interpreted as indicating the elective nature of this decision. Therefore viral load was not included as a Group B
criterion after 2000.
Johnson et al. AIDS Research and Therapy 2014, 11:10 Page 3 of 10
http://www.aidsrestherapy.com/content/11/1/10than six months of follow-up between the date of
classification and last study visit were excluded from
analysis (N = 77).
 Group C – those participants who may have
electively started HAART; initiators started HAART
prior to being categorized into either Groups A or
B; delayers were HAART-naive as of their last study
visit and had not yet been categorized into Groups
A or B.
The different initiator/delayer classification timeframes
for Groups A and B were selected based on practice pat-
terns unique to the military, specifically that some partici-
pants do not live near an MTF offering specialty HIV care
and receive care on an approximately four to six month
cycle. Participants could be evaluated in more than one
group if they later met criteria for inclusion in another
group, up until the time when they initiated HAART, at
which point they could no longer be analyzed in any other
group.
To further assess for evidence of disparity, the analysis
was repeated evaluating the association between study fac-
tors and starting primary pneumocystis pneumonia (PCP)
prophylaxis within four months of the first verified CD4
count <200 cells/mm3 (i.e. at least one subsequent CD4
count within three months that was also <200 cells/mm3).
This analysis included those without a history of PCP who
met CD4 criteria for primary PCP prophylaxis and had
not yet started this treatment. Initiators started PCP
prophylaxis within four months and delayers did not.
Data analysis
Factors studied included demographic characteristics (age,
gender, self-reported race/ethnicity, duty status, and rank),
HIV-specific factors (time since HIV infection, CD4 cell
counts, HIV RNA levels, history of prior AIDS-defining
condition and history of HIV symptoms), comorbidmedical conditions (cerebrovascular disease, chronic kid-
ney disease, chronic obstructive pulmonary disease, chronic
viral hepatitis, cirrhosis, coronary artery disease, diabetes,
and malignancy other than basal cell carcinoma) and his-
tory of a mental health disorder (anxiety disorder, bipolar
disorder, major depression, obsessive-compulsive disorder,
post-traumatic stress disorder, schizophrenia, substance
abuse, and prior suicide attempt).
Descriptive statistics are presented as means with stand-
ard deviations (SD) or medians with interquartile ranges
(IQR). For Groups A and B, factors were compared as of
the date the participant was categorized into the group.
For Group C, comparisons used the date of HAART initi-
ation for initiators and date of last visit for delayers.
Within each group, study variables among participants
who initiated vs. delayed HAART were compared using
logistic regression. Analyses were repeated among partici-
pants who initiated vs. delayed primary PCP prophylaxis
when indicated. All multivariate models adjusted for gen-
der, age, race/ethnicity, marital status, rank, duty status,
military site, branch of service, duration of HIV disease,
prior ART use, prior comorbid illnesses, and history of
mental health diagnosis. The Group A analyses addition-
ally adjusted for HIV RNA and reason for classification
(CD4 cell count <200 cells/mm3, AIDS-defining condition,
or severe symptoms). The Group C analyses additionally
adjusted for HIV RNA and CD4 cell count. To account
for changes in recommendations, models for the analyses
were stratified by HIV treatment guideline era. Odds ratios
are given with 95% confidence intervals (CI). All p-values
are two-sided. Analyses were conducted using SAS (ver-
sion 9.1, Cary, NC).
Results
We evaluated 1262 participants who were predominantly
male (94%) with a mean age of 33.8 years (SD 8.7). Forty
percent of participants were Caucasian, 46% African
Johnson et al. AIDS Research and Therapy 2014, 11:10 Page 4 of 10
http://www.aidsrestherapy.com/content/11/1/10American, 10% Hispanic and 5% other ethnic groups.
Sixty-two participants were evaluated in both Group A
and Group B.
Of the 1262 participants, 208 were categorized as having
a definite indication to start HAART (Group A), including
99 (48%) due to a CD4 count below 200 cells/mm3, 99
(48%) due to severe symptoms, and 10 (5%) for an AIDS-
defining condition. Of these, 121 (58%) initiated HAART
within 4 months of indication, with a median of 11 days
(IQR 3-36) from indication to HAART initiation. The
remaining 87 (42%) were defined as delayers; reasons for
delay were not captured in the study database. The me-
dian CD4 cell count was 176 (IQR 131 – 207) among initi-
ators and 417 (IQR 267-554) among delayers.
In both the univariate (UV) and multivariate (MV)
models, race/ethnicity and other demographic variables
were not significantly associated with the timing of
HAART in Group A. Participants with higher HIV RNA
levels were more likely to initiate HAART (OR 2.19,
95% CI 1.32-3.64 per 1-log10 increase). Participants clas-
sified into Group A due to severe symptoms were less
likely to initiate HAART when compared to those classi-
fied because their CD4 cell count fell below 200 cells/
mm3 (OR = 0.07, 95% CI 0.03-0.17). There was no sig-
nificant difference between participants classified into
Group A for an AIDS-defining condition when com-
pared with those classified for a CD4 cell count <200
cells/mm3 (OR = 0.36, 95% CI 0.07 – 1.93) (Table 2).
Group B included 637 participants, with 248 (39%) ini-
tiators and 389 (61%) delayers. Of these, 476 (75%) were
classified into this group because of CD4 count, 82
(13%) due to HIV RNA level, and 79 (12%) because of
meeting a combination of these factors. As in Group A,
race/ethnicity was not significantly associated with the
timing of HAART in Group B in either model. Factors
associated with initiating HAART in both the UV and
MV models were duration of HIV infection (OR 0.87,
95% CI 0.0.80-0.94 per 1-year increase) and prior non-
HAART antiretroviral therapy (ART) use (OR 0.51, 95%
CI 0.27-0.97). Additional factors that were significant
only in univariate analyses were age, military status, and
comorbid illnesses (Table 3).
Among the 479 participants in Group C, 144 (30%)
participants initiated HAART. In UV models, African
Americans were half as likely to initiate HAART in this
group when compared to Caucasians (OR 0.50, 95% CI
0.32-0.78). In the MV model, African American race
remained significantly associated with delayed HAART
initiation (OR 0.49, 95% CI 0.25-0.97) (Table 4).
There were 408 participants with a CD4 count <200
cells/mm3 included in the analysis of factors associated
with the initiation of primary PCP prophylaxis. Race/eth-
nicity, age, and gender were not associated with the tim-
ing of primary PCP prophylaxis. HAART-experiencedparticipants were less likely to start PCP prophylaxis
(OR 0.48, 95% CI 0.25-0.91, compared to ART-naive
participants) as were those with CD4 cell counts closer
to 200 cells/mm3 (OR 0.55, 95% CI 0.42 – 0.70 per 50
cells/mm3) (Table 5).
Discussion
The interplay of factors surrounding the timing of
HAART initiation is complex, and involves not only bio-
logic factors such as immune function and disease pro-
gression, but also psychosocial and systems-based factors.
A better understanding of these factors may help eliminate
treatment barriers and enable healthcare providers to offer
optimal care to all patients with HIV. This study’s findings
show that in an environment providing no-fee open access
care, certain factors previously demonstrated to affect the
timing of HAART, namely race/ethnicity, age, gender and
depression did not have the same impact in most patients
in this cohort. This remained true with respect to timely
initiation of primary PCP prophylaxis when indicated.
However in the subset of patients in Group C who elec-
tively started HAART at higher CD4 cell counts without
an indication, African American race/ethnicity was associ-
ated with lower odds of initiation.
The Department of Defense provides a healthcare sys-
tem ensuring access to visits and medications for its
beneficiaries. In addition, keeping appointments is rein-
forced for active duty members by their chain of com-
mand. This practice and the military’s culture of health
provide a potential explanation for the absence of a sta-
tistically significant difference in the timing of HAART
initiation when indicated across demographic groups in
this cohort. However the potential impact of command-
directed follow-up among active duty personnel may be
suggested by the observation of a non-significant trend
towards lower odds of HAART initiation among retired
participants. Previous studies have underscored the im-
portance of regular clinic follow-up on appropriate
HAART use. In one study which showed a longer time
to HAART initiation among black patients, the most
common reasons for delays in referral to case confer-
ences (where decisions were made about HAART) were
lack of regular follow-up, active substance use, and the
patient’s desire to not use HAART [21]. There are fewer
issues with access and follow-up in the U.S. military
healthcare system. Also, the DoD Drug Demand Reduc-
tion Program with random urine drug screening has
been very successful in decreasing substance abuse
among active duty, especially with regard to intravenous
drug use [22]. Cultural differences in medication uptake
and adherence have yet to be fully explored in the military
setting, but preliminary evaluation suggests HAART ad-
herence levels are equally high among a subset of African
Americans and Caucasians [18].
Table 2 Factors associated with the initiation of HAART from 1998-2009 among those with a definite indication to
start (Group A)
Univariate models Multivariate model*
Initiators (N = 121)
N (%) or median (IQR)
Delayers (N = 87)
N (%) or median (IQR)
OR (95% CI) P OR (95% CI) P
Demographics
Gender (% Male) 107 (88%) 77 (89%) 0.99 (0.42 - 2.35) 0.99 0.55 (0.11 - 2.61) 0.45
Age 35.1 ± 9.4 33.9 ± 9.7 1.01 (0.98 - 1.04) 0.35 1.03 (0.98 - 1.08) 0.26
Race/ethnicity
Caucasian 41 (33.9%) 35 (40.2%) Referent Referent
American 53 (43.8%) 41 (47.1%) 1.10 (0.60 - 2.03) 0.75 0.69 (0.28 - 1.71) 0.43
Hispanic/Latino/other 27 (22.3%) 11 (12.6%) 2.09 (0.91 - 4.82) 0.08 1.71 (0.53 - 5.50) 0.37
Marital status (% married) 45 (38.5%) 27 (32.5%) 1.30 (0.72 - 2.34) 0.39 1.08 (0.46 - 2.56) 0.86
Military characteristics
Rank
Officer/warrant 8 (6.6%) 8 (9.2%) 0.70 (0.25 - 1.95) 0.50 0.34 (0.08 - 1.49) 0.15
Enlisted 100 (82.6%) 70 (80.5%) Referent Referent
N/A 13 (10.7%) 9 (10.3%) 1.01 (0.41 - 2.49) 0.98 0.73 (0.08 - 6.73) 0.78
Duty status
Active 83 (68.6%) 66 (75.9%) Referent Referent
Retired 22 (18.2%) 14 (16.1%) 1.23 (0.59 - 2.60) 0.58 1.34 (0.35 - 5.19) 0.67
Dependent 15 (12.4%) 7 (8.0%) 1.68 (0.65 - 4.37) 0.28 2.56 (0.29 - 22.80) 0.40
HIV characteristics
Duration of HIV infection (years) 1.3 (0.1 - 4.8) 1.9 (0.2 - 7.1) 0.95 (0.90 - 1.02) 0.14 0.92 (0.83 - 1.03) 0.15
Log10 HIV RNA 4.7 (4.3 - 5.2) 4.3 (3.7 - 4.8) 2.10 (1.46 - 3.04) <0.001 2.19 (1.32 - 3.64) 0.002
CD4 count in cells/mm3 176.0 (131.0 - 207.0) 417.0 (267.0 - 554.0)
Prior ART (non-HAART) use 18 (15%) 13 (15%) 0.99 (0.46 - 2.16) 0.99 0.97 (0.26 - 3.55) 0.96
Prior comorbid illness(es) 10 (8%) 10 (11%) 0.69 (0.28 - 1.75) 0.44 0.30 (0.08 - 1.14) 0.08
History of mental health diagnosis
Depression 11 (9%) 9 (10%) 0.87 (0.34 - 2.21) 0.77 0.65 (0.18 - 2.42) 0.52
Other mental health diagnosis 9 (7%) 6 (7%) 1.07 (0.36 - 3.14) 0.90 1.13 (0.27 - 4.83) 0.86
None 101 (83%) 72 (83%) Referent Referent
Reason for classification
Severe symptoms 34 (28%) 65 (75%) 0.12 (0.06 - 0.22) <0.001 0.07 (0.03 - 0.17) <0.001
AIDS defining condition 6 (5%) 4 (5%) 0.33 (0.09 - 1.30) 0.11 0.36 (0.07 - 1.93) 0.23
CD4 count <200 cells/mm3 81 (67%) 18 (21%) Referent Referent
*Multivariate model additionally adjusts for branch and site of service.
P-values < 0.05 are presented in bold text.
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Caucasians to electively start HAART at higher CD4
counts. And while there were no statistically significant eth-
nic differences among those with an indication for HAART,
there remained a trend towards lower odds of HAART ini-
tiation at lower CD4 count thresholds among African
American participants when compared with Caucasian
participants. A number of previous studies observed dis-
parities in HAART use among certain race/ethnicgroups and women although these did not specifically
evaluate the elective initiation of HAART at high CD4
counts [8-10,14,21,23-26]. While the etiology of these
disparities is largely attributed to differences in health-
care access, other factors have also been shown to con-
tribute and perhaps offer an explanation for the findings
in this study. For example, racial discordance of the
physician-patient relationship may be associated with
cultural miscommunication that could explain delays in
Table 3 Factors associated with the initiation of HAART from 1998-2009 among those classified into the consider
offering treatment group (Group B)
Univariate models Multivariate model*,**
Initiators (N = 248)
N (%) or median (IQR)
Delayers (N = 389)
N (%) or median (IQR)
OR (95% CI) p OR (95% CI) p
Demographics
Gender (% Male) 236 (95%) 368 (95%) 1.04 (0.50 - 2.16) 0.92 1.19 (0.44 - 3.22) 0.74
Age 31.7 ± 7.3 33.1 ± 8.4 0.98 (0.96 - 1.00) 0.04 1.00 (0.97 - 1.03) 0.93
Race/ethnicity
Caucasian 102 (41.1%) 141 (36.2%) Referent Referent
African American 109 (44.0%) 195 (50.1%) 0.80 (0.56 - 1.13) 0.20 0.83 (0.56 - 1.24) 0.37
Hispanic/Latino/other 37 (14.9%) 53 (13.6%) 0.91 (0.55 - 1.49) 0.71 1.05 (0.60 - 1.82) 0.88
Marital status (% married) 83 (34.6%) 120 (33.9%) 1.05 (0.74 - 1.49) 0.78 1.10 (0.75 - 1.62) 0.62
Military characteristics
Rank
Officer/warrant 19 (7.7%) 28 (7.2%) 1.01 (0.55 - 1.86) 0.97 1.14 (0.56 - 2.32) 0.72
Enlisted 214 (86.3%) 334 (85.9%) Referent Referent
N/A 15 (6.0%) 27 (6.9%) 0.95 (0.49 - 1.84) 0.88 0.97 (0.20 - 4.77) 0.97
Duty status
Active 219 (88.3%) 297 (76.3%) Referent Referent
Retired 17 (6.9%) 77 (19.8%) 0.34 (0.19 - 0.59) <0.001 0.61 (0.28 - 1.32) 0.21
Dependent 12 (4.8%) 15 (3.9%) 1.15 (0.53 - 2.52) 0.72 2.20 (0.36 - 13.35) 0.39
HIV characteristics
Duration of HIV infection (years) 0.3 (0.1 - 1.9) 1.8 (0.2 - 5.2) 0.84 (0.78 - 0.89) <0.001 0.87 (0.80 - 0.94) <0.001
Log10 HIV RNA 4.5 (4.1 - 4.9) 4.1 (3.4 - 4.5)
CD4 cell count 323.0 (287.0 - 422.5) 352.0 (316.0 - 461.0)
Prior ART (non-HAART) use 22 (9%) 100 (26%) 0.30 (0.18 - 0.51) <0.001 0.51 (0.27 - 0.97) 0.04
Prior comorbid Illness (es) 12 (5%) 40 (10%) 0.45 (0.23 - 0.89) 0.02 0.76 (0.35 - 1.66) 0.49
History of mental health diagnosis
Depression 18 (7%) 37 (10%) 0.73 (0.40 - 1.32) 0.30 1.02 (0.53 - 1.98) 0.95
Other mental health diagnosis 13 (5%) 20 (5%) 0.96 (0.47 - 1.99) 0.92 1.16 (0.53 - 2.55) 0.71




168 (68%) 308 (79%)
HIV RNA >20,000
copies/ml (1998-2000 only)
32 (13%) 50 (13%)
CD4 <500 and HIV >20,000
copies/ml (1998-2000 only)
48 (19%) 31 (8%)
*All models are stratified by guideline era (1998-2000, 2001-2009).
**Multivariate model additionally adjusts for branch and site of service.
P-values < 0.05 are presented in bold text.
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ported that their provider “knows me as a person” were
more likely to receive HAART than those who did not re-
port this belief [13]. Other factors may also impact de-
cisions about HAART including health literacy and
attitudes toward health [28,29]. It is important to note thatnot all studies have shown racial/ethnic differences in the
receipt of HAART. In a study performed among HIV-
positive patients in Denmark, where healthcare is free,
both white and nonwhite patients had similar rates of re-
ceiving HAART, and race/ethnicity did not have an appar-
ent effect on the outcomes associated with HAART [30].
Table 4 Factors associated with the elective initiation of HAART from 1998-2009, Group C
Univariate models Multivariate model*,**
Initiators (N = 144)
N (%) or median (IQR)
Delayers (N = 335)
N (%) or median (IQR)
OR (95% CI) p OR (95% CI) P
Demographics
Gender (% Male) 140 (97%) 310 (93%) 3.19 (1.08 - 9.47) 0.04 1.50 (0.34 - 6.63) 0.59
Age 33.6 ± 9.4 32.2 ± 8.5 1.01 (0.99 - 1.04) 0.20 1.04 (0.99 - 1.09) 0.08
Race/ethnicity
Caucasian 70 (48.6%) 117 (34.9%) Referent Referent
African American 47 (32.6%) 162 (48.4%) 0.50 (0.32 - 0.78) 0.002 0.49 (0.25 - 0.97) 0.04
Hispanic/Latino/other 27 (18.8%) 56 (16.7%) 0.88 (0.51 - 1.53) 0.66 0.85 (0.40 - 1.82) 0.68
Marital status (% married) 38 (27.7%) 95 (31.8%) 0.67 (0.41 - 1.08) 0.10 0.67 (0.34 - 1.33) 0.25
Military characteristics
Rank
Officer/warrant 23 (16.0%) 30 (9.0%) 1.79 (0.99 - 3.24) 0.05 1.30 (0.56 - 3.04) 0.54
Enlisted 116 (80.6%) 275 (82.1%) Referent Referent
N/A 5 (3.5%) 30 (9.0%) 0.27 (0.10 - 0.74) 0.01 1.53 (0.19 - 12.62) 0.69
Duty status
Active 121 (84.0%) 284 (84.8%) Referent Referent
Retired 18 (12.5%) 32 (9.6%) 1.09 (0.58 - 2.06) 0.78 0.52 (0.13 - 2.13) 0.36
Dependent 5 (3.5%) 19 (5.7%) 0.50 (0.18 - 1.39) 0.18 0.38 (0.04 - 3.52) 0.40
HIV characteristics
Duration of HIV Infection (years) 1.2 (0.3 - 4.0) 2.1 (0.7 - 4.8) 0.92 (0.86 - 0.98) 0.009 0.91 (0.80 - 1.04) 0.18
Log10 HIV RNA
+ 4.5 (3.7 - 5.0) 3.7 (3.0 - 4.4) 3.11 (2.30 - 4.21) <0.001 3.25 (2.15 - 4.93) <0.001
CD4 cell count*** 496.5 (398.5 - 627.5) 606.0 (496.0 - 775.0) 0.83 (0.78 - 0.89) <0.001 0.82 (0.75 - 0.90) <0.001
Prior ART (non-HAART) use 29 (20%) 19 (6%) 3.49 (1.82 - 6.71) <0.001 50.56 (9.94 - 257.1) <0.001
Prior comorbid illness (es) 12 (8%) 21 (6%) 1.32 (0.62 - 2.77) 0.47 0.51 (0.16 - 1.62) 0.25
History of mental health diagnosis
Depression 14 (10%) 43 (13%) 0.74 (0.39 - 1.41) 0.36 0.44 (0.17 - 1.10) 0.08
Other mental health diagnosis 8 (6%) 35 (10%) 0.52 (0.23 - 1.15) 0.11 0.37 (0.13 - 1.04) 0.06
None 122 (85%) 257 (77%) Referent Referent
*All models are stratified by guideline era (1998-2000, 2001-2009).
**Multivariate model additionally adjusts for branch and site of service.
+Per 1.0 log10 increase.
***Univariate and Multivariate models are per 50 cells/mm3.
P-values < 0.05 are presented in bold text.
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HAART initiation in this study is important because some
studies have demonstrated a differential response to
HAART between Caucasian and non-Caucasian groups
[16,17,21,31,32]. In an analysis of antiretroviral-naïve pa-
tients with HIV who started HAART between 1997 and
2003, African American race/ethnicity was associated with
failure to reach virologic suppression at 12 months [16]
and at 6 months and 12 months after initiating HAART
[17]. And despite continuous use of HAART, black
women experienced increased rates of AIDS-defining ill-
ness and death from AIDS when compared with white
women [32]. Interestingly, two studies suggest that in spite
of decreased rates of virologic suppression, AfricanAmericans and Caucasians treated with HAART in the
DoD have equivalent long-term outcomes [15,18]. Phar-
macogenomic and adherence differences are being ex-
plored as possible explanations for the lower virologic
suppression rates.
Depression was not associated with the timing of
HAART in this study among those with an indication to
start, although it has been shown to impact the decision to
start HAART in some previous studies [33,34] but not all
[35]. There was a delay in HAART initiation in Group A
due to the presence of severe symptoms, which may reflect
the high median CD4 cell count among delayers in this
group, a prioritization of disease management, or possibly
a concern about immune reconstitution inflammatory
Table 5 Factors associated with early initiation of primary PCP prophylaxis from 1998-2009
Univariate models Multivariate model*
Initiators (N = 156)
N (%) or median (IQR)
Delayers (N = 252)
N (%) or median (IQR)
OR (95% CI) p OR (95% CI) P
Demographics
Gender (% Male) 144 (92%) 227 (90%) 1.32 (0.64 - 2.71) 0.45 1.00 (0.33 - 3.03) >0.99
Age 36.9 (29.2 - 43.0) 37.4 (32.2 - 42.5) 0.99 (0.97 - 1.01) 0.36 0.98 (0.95 - 1.01) 0.27
Race/ethnicity
Caucasian 61 (39%) 100 (40%) Referent Referent
African American 72 (46%) 122 (48%) 0.97 (0.63 - 1.49) 0.88 1.21 (0.71 - 2.09) 0.48
Hispanic/Latino/other 23 (15%) 30 (12%) 1.26 (0.67 - 2.36) 0.48 1.35 (0.61 - 3.00) 0.46
Marital status (% married) 63 (41%) 71 (31%) 1.50 (0.98 - 2.30) 0.06 1.52 (0.89 - 2.59) 0.12
Military characteristics
Rank
Officer/warrant 19 (12%) 24 (10%) 1.33 (0.70 - 2.54) 0.38 1.76 (0.74 - 4.15) 0.20
Enlisted 121 (78%) 199 (79%) Referent Referent
N/A 16 (10%) 24 (10%) 1.12 (0.57 - 2.20) 0.73 1.72 (0.54 - 5.47) 0.36
Duty status
Active 82 (53%) 109 (43%) Referent Referent
Retired 63 (40%) 118 (47%) 0.71 (0.47 - 1.08) 0.11 1.16 (0.59 - 2.25) 0.67
Dependent 11 (7%) 25 (10%) 0.58 (0.27 - 1.26) 0.17 0.36 (0.09 - 1.53) 0.17
HIV characteristics
Duration of HIV infection (years) 2.5 (0.1 - 8.8) 6.6 (1.8 - 10.9) 0.93 (0.89 - 0.97) <0.001 0.99 (0.93 - 1.05) 0.70
Log10 HIV RNA 4.8 (4.3 - 5.2) 4.5 (3.6 - 5.0) 1.49 (1.21 - 1.83) <0.001 1.25 (0.98 - 1.60) 0.07
CD4 count* 130.0 (68.5 - 167.0) 169.0 (131.5 - 187.0) 0.59 (0.49 – 0.72) <0.001 0.55 (0.42 – 0.70) <0.001
Prior ART use
None 92 (59%) 81 (32%) Referent Referent
ART 14 (9%) 24 (10%) 0.51 (0.25 - 1.06) 0.07 0.81 (0.30 - 2.15) 0.67
HAART 50 (32%) 147 (58%) 0.30 (0.19 - 0.46) <0.001 0.48 (0.25 - 0.91) 0.03
Prior AIDS 24 (15%) 36 (14%) 1.09 (0.62 - 1.91) 0.76 1.00 (0.45 - 2.19) >0.99
History of mental health diagnosis
Depression 19 (12%) 46 (18%) 0.63 (0.35 - 1.13) 0.12 0.82 (0.41 - 1.65) 0.58
Other mental health diagnosis 13 (8%) 16 (6%) 1.24 (0.58 - 2.68) 0.58 1.52 (0.61 - 3.79) 0.36
None 124 (79%) 190 (75%) Referent Referent
*Univariate and Multivariate models are per 50 cells/mm3.
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counts. Prior mono- and dual-NRTI use was associated
with decreased odds of starting HAART in Group B, but
increased odds in Group C. This effect was highly associ-
ated with calendar year and may reflect delays in changing
to HAART in the early HAART era in participants stable
on non-HAART ART in Group B versus a preference
for newer therapies in those electing to start HAART in
Group C. A similar phenomenon in the early HAART era
is suggested in a study examining the reasons why 28 of
60 patients treated for HIV in a U.S. health clinic were not
treated with HAART in 1997-1998 in accordance with
DHHS guidelines at the time [36]. Another study alsosuggested delays in transitioning to the use of protease in-
hibitors in a U.S. practice in 1996 among 190 patients;
higher CD4 cell count (200-500 cells/mm3) was a promin-
ent factor in multivariate models [37].
There are some study limitations. It is a retrospective
analysis covering a broad timeframe and involves five DoD
research sites among which practice patterns may vary.
Statistical models were adjusted to account for site of visit
and service affiliation. While the cohort has a balance of
male African American and Caucasian participants, other
ethnic groups and women are represented in much smaller
proportions, making it difficult to draw conclusions about
the timing of HAART among these groups. Overall, the
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http://www.aidsrestherapy.com/content/11/1/10cohort is relatively small, and while we observed many
trends that did not reach statistical significance, it is pos-
sible that these trends would represent clinically important
differences in a larger cohort. Further, it is likely that there
are additional confounding factors that we were not able
to fully account for in the analysis. The criteria for deter-
mining eligibility for HAART initiation in this study are
limited to the DHHS guidelines, even though other soci-
eties in the U.S. and worldwide have published guidelines
that may have influenced practice patterns. And import-
antly, there are limited data on substance use in this co-
hort, although it is estimated to be quite low, with no
IVDU reported at last survey [22].
Conclusion
In a cohort with free access to HIV care and medica-
tions, race/ethnicity, age, and gender did not impact
HAART timing among those with an indication for ther-
apy, but African American race/ethnicity was associated
with lower odds of electively initiating antiretrovirals.
This study reinforces that free healthcare can potentially
overcome some of the observed disparities in HIV care,
particularly those related to access. However additional
unmeasured factors may result in persistent differences
in elective care decisions.
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